The scientific basis of urinary stone formation

The Scientific Basis of Urology, Second Edition

Volumn , Issue , 2004, Pages 205-227

  Robertson, William G ^a  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057213831     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (132)

1. Williams RE. Long-term survey of 538 patients with upper urinary tract stone. B J Urol 1963; 35: 416–437
2. Pearl MS, Clayman RV. Outcomes and selection of surgical therapies of stones in the kidney and ureter. In: Coe FL, Favus MJ, Pak CYC, Parks JH et al, eds. Kidney Stones – Medical and Surgical Management. Philadelphia: Lippincott-Raven, 1996: 709–755
3. Robertson WG. The economic case for the biochemical screening of stone patients. In: Rodgers AL, Hibbert BE, Hess B, Khan S et al, eds. Urolithiasis 2000. Cape Town: University of Cape Town, 2000: 403–405
4. Parks JH, Coe FL. The financial effects of kidney stone prevention. Kidney Int 1996; 50: 1706–1712
5. Andersen DA. Environmental factors in the aetiology of urolithiasis. In: Cifuentes Delatte L, Rapado A, Hodgkinson A, eds. Urinary Calculi. Basel: Karger, 1973: 130–144
6. Robertson WG, Peacock M, Heyburn PJ, Hanes FA et al. The risk of calcium stone-formation in relation to affluence and dietary animal protein. In: Brockis JG, Finlayson B, eds. Urinary Calculus. Littleton, MA: PSG Publishing, 1981: 3–12
7. Robertson WG, Whitfield HN, Unwin RJ, Mansell MA et al. Possible causes of the changing pattern of the age of onset of urinary stone disease in the UK. In: Rodgers AL, Hibbert BE, Hess B, Khan S et al, eds. Urolithiasis 2000. Cape Town: University of Cape Town, 2000: 366–368
8. Robertson WG. Urinary tract calculi. In: Nordin BEC, Need AG, Morris HA, eds. Metabolic Bone and Stone Disease. 3rd edn. Edinburgh: Churchill Livingstone, 1993: 249–311
9. Griffith DP, Osborne CA. Infection (urease) stones. Miner Electrolyte Metab 1987; 13: 278–285
10. Wickham JEA. Matrix and the infective renal calculus. Br J Urol 1976; 47: 727–732
11. Boyce WH, King JS. Present concepts concerning the origin of matrix and stones. Ann N Y Acad Sci 1963; 104: 563–578
12. Morse RM, Resnick MI. A new approach to the study of urinary macromolecules as a participant in calcium oxalate crystallization. J Urol 1988; 139: 869–873
13. Morse RM, Resnick MI. A study of the incorporation of urinary macromolecules onto crystals of different mineral compositions. J Urol 1989; 141: 641–644
14. Robertson WG. Measurement of ionized calcium in biological fluids. Clin Chim Acta 1969; 24: 149–157
15. Werness P, Brown C, Smith LH, Finlayson B. EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol 1985; 134: 1242–1244
16. Vermeulen CW, Ellis JE, Hsu TC. Experimental observations on the pathogenesis of urinary calculi. J Urol 1966; 95: 681–690
17. Robertson WG, Peacock M, Nordin BEC. Calcium crystalluria in recurrent renal stone-formers. Lancet 1969; 2: 21–24
18. Kok DJ, Papapoulos SE, Bijvoet OLM. Crystal agglomeration is a major element in calcium oxalate urinary stone-formation. Kidney Int 1990; 37: 51–56
19. Finlayson B, Reid F. The expectation of free and fixed particles in urinary stone disease. Investig Urol 1978; 15: 442–448
20. Kumar S, Sigmon D, Miller T, Carpenter B et al. A new model of nephrolithiasis involving tubular dysfunction/injury. J Urol 1991; 146: 1384–1389
21. Bigelow MW, Wiessner JH, Kleinman JG, Mandel NS. Calcium oxalate crystal attachment to cultured kidney epithelial cell lines. J Urol 1998; 160: 1528–1532
22. Verkoelen CF, van der Boom BG, Houtsmuller AB, Schröder FH et al. Increased calcium oxalate monohydrate crystal binding to injured tubular epithelial cells in culture. Am J Physiol 1998; 274: F958–F965
23. Scheid C, Koul H, Hill WA, Luber-Narod J et al. Oxalate toxicity in LLC-PK1 cells: role of free radicals. Kidney Int 1996; 49: 413–419
24. Lieske JC, Leonard R, Swift HS, Toback FG. Adhesion of calcium oxalate monohydrate crystals to anionic sites of renal epithelial cells. Am J Physiol 1996; 270: F192–F199
25. Koul H, Menon M, Koul S, Santosham V, Snow M. Effect of oxalate on calcium oxalate crystal adherence to renal epithelial cells in culture. In: Rodgers AL, Hibbert BE, Hess B, Khan S et al, eds. Urolithiasis 2000. Cape Town: University of Cape Town, 2000: 267–269
26. Robertson WG, Peacock M, Nordin BEC. Calcium oxalate crystalluria and urine saturation in recurrent renal stone-formers. Clin Sci 1971; 40: 365–374
27. Kok DJ, Khan SR. Calcium oxalate nephrolithiasis, a free or fixed particle disease? J Urol 1994; 46: 847–854
28. Borden TA, Lyon ES. The effects of magnesium and pH on experimental calcium oxalate stone disease. Investig Urol 1969; 6: 412–422
29. Meyer JL, Smith LH. Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Investig Urol 1975; 13: 36–39
30. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 1962; 203: 671–675
31. Fleisch H, Bisaz S. The inhibitory effect of pyrophosphate on calcium oxalate precipitation and its relation to urolithiasis. Experientia 1964; 20: 276–277
32. Meyer JL, McCall JT, Smith LH. Inhibition of calcium phosphate crystallization by nucleoside phosphates. Calcif Tissue Res 1974; 15: 289–293
33. Howard JE, Thomas WC, Barker LM, Smith LH et al. The recognition and isolation from urine and serum of a peptide inhibitor to calcification. Johns Hopkins Med J 1967; 120: 119–136
34. Robertson WG, Peacock M, Nordin BEC. Inhibitors of the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 1973; 43: 31–37
35. Ryall RL, Harnett RM, Marshall VR. The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 1981; 112: 349–356
36. Robertson WG, Scurr DS, Bridge CM. Factors influencing the crystallization of calcium oxalate in urine – a critique. J Crystal Growth 1981; 53: 182–194
37. Worcester EM, Nakagawa Y, Coe FL. Glycoprotein calcium oxalate crystal growth inhibitor in urine. Miner Electrolyte Metab 1987; 13: 267–272
38. Worcester EM, Nakagawa Y, Wabner CL, Kumar S et al. Crystal adsorption and growth slowing by nephrocalcin, albumin and Tamm-Horsfall protein. Am J Physiol 1988; 255: F1197–F1205
39. Nakagawa Y, Ahmed MA, Hall SL, Deganello S et al. Isolation from human calcium oxalate stones of nephrocalcin, a glycoprotein inhibitor of calcium oxalate crystal growth. Evidence that nephrocalcin from patients with calcium oxalate nephrolithiasis is deficient in gamma-carboxyglutamic acid. J Clin Invest 1987; 79: 1782–1787
40. Hess B, Nakagawa Y, Coe FL. Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 1989; 257: F99–F106
41. Coe FL, Parks JH. Defenses of an unstable compromise: crystallization inhibitors and the kidney’s role in mineral regulation. Kidney Int 1990; 38: 625–631
42. Pillay SN, Asplin JR, Coe FL. Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization. Am J Physiol 1998; 275: F255–F261
43. Shiraga H, Min W, Van Dusen WJ, Clayman MD et al. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 1992; 89: 426–430
44. Dussol B, Geider S, Lilova A, Leonetti F et al. Analysis of the soluble matrix of five morphologically different kidney stones. Urol Res 1995; 23: 45–51
45. Stapleton AMF, Dawson CJ, Grover PK, Hohmann A et al. Further evidence linking urolithiasis and blood coagulation: urinary prothrombin fragment 1 is present in stone matrix. Kidney Int 1996; 49: 880–888
46. Grover PK, Ryall RL. Inhibition of calcium oxalate crystal growth and aggregation by prothrombin and its fragments in vitro: relationship between protein structure and inhibitory activity. Eur J Biochem 1999; 263: 50–56
47. Dawson CJ, Grover PK, Ryall RL. Inter-alpha-inhibitor in urine and calcium oxalate urinary crystals. Br J Urol 1998; 81: 20–26
48. Spector AR, Gray A, Prien EL. Kidney stone matrix. Differences in acidic protein composition. Investig Urol 1976; 13: 387–389
49. Lian JB, Prien EL, Glimcher MJ, Gallop PM. The presence of protein-bound c-carboxyglutamic acid in calcium-containing renal calculi. J Clin Invest 1977; 59: 1151–1157
50. Jones WT, Resnick MI. The characterization of soluble matrix proteins in selected human renal calculi using two-dimensional polyacrylamide gel electrophoresis. J Urol 1990; 144: 1010–1014
51. Rose GA, Sulaiman S. Tamm-Horsfall mucoproteins promote calcium oxalate crystal formation in urine: quantitative studies. J Urol 1982; 127: 177–179
52. Scurr DS, Robertson WG. Modifiers of calcium oxalate crystallization found in urine. III. Studies on the role of Tamm-Horsfall mucoprotein and of ionic strength. J Urol 1986; 136: 505–507
53. Grover PK, Ryall RL, Marshall VR. Does Tamm- Horsfall mucoprotein inhibit or promote calcium oxalate crystallization in human urine? Clin Chim Acta 1990; 190: 223–238
54. Robertson WG. ‘Take-home message’ on the epidemiology and basic science of stone-formation. In: Rodgers AL, Hibbert BE, Hess B, Khan S et al, eds. Urolithiasis 2000. Cape Town: University of Cape Town, 2000: 841–849
55. Dent CE, Senior B, Walshe JM. The pathogenesis of cystinuria. II. Polarographic studies of the metabolism of sulphur-containing amino acids. J Clin Invest 1954; 33: 1216–1226
56. Milne MD, Asatoor AM, Edwards KDG, Loughridge LW. The intestinal absorption defect in cystinuria. Gut 1961; 2: 323–337
57. Ettinger B, Kolb FO. Factors involved in crystal formation in cystinuria. In vivo and in vitro crystallization dynamics and a simple colorimetric assay for cystine. J Urol 1971; 106: 106–110
58. Dahlberg PJ, Van den Berg CJ, Kurtz SB, Wilson DM et al. Clinical features and management of cystinuria. Mayo Clin Proc 1977; 52: 533–542
59. Crawhall JC, Purkiss P, Watts RWE, Young EP. The excretion of amino acids by cystinuric patients and their relatives. Ann Hum Genet 1969; 33: 149–169
60. Dent CE, Friedman M, Green H, Watson LCA. Treatment of cystinuria. Br Med J 1965; 1: 403–407
61. Dent CE, Senior B. Studies on the treatment of cystinuria. Br J Urol 1955; 27: 317–332
62. Crawhall JC, Scowen EF, Watts RWE. Effect of penicillamine on cystinuria. Br Med J 1963; 1: 588–590
63. Stokes GS, Potts JT, Lotz M, Bartter FC. New agent in the treatment of cystinuria: N-acetyl-D-penicillamine. BMJ 1968; 1: 284–288
64. Remien A, Kallistratos G, Burchardt P. Treatment of cystinuria with thiola (a-mercapto-propionyl glycine). Eur Urol 1975; 1: 227–228
65. Pak CYC, Fuller C, Sakhaee K, Zerwekh JE et al. Management of cystine nephrolithiasis with mercaptopropionylglycine. J Urol 1986; 136: 1003–1008
66. Frimpter GW. Medical management of cystinuria. Am J Med Sci 1968; 255: 348–357
67. Koide Y, Kinoshita K, Takemoto M, Yachiku S et al. Conservative treatment of cystine calculi: effect of oral alpha-mercaptopropionylglycine on cystine stone dissolution and on prevention of stone recurrence. J Urol 1982; 128: 513–516
68. Gutman AB, Yü TF. Uric acid nephrolithiasis. Am J Med 1968; 45: 657–779
69. Seegmiller JE, Grayzel AI, Laster L, Liddle L. Uric acid production in gout. J Clin Invest 1961; 40: 1304–1314
70. Atsmon A, De Vries A, Frank M. Uric Acid Lithiasis. Amsterdam: Elsevier, 1963
71. Metcalfe-Gibson A, MacCallum FM, Morrison RBI, Wrong O. Urinary excretion of hydrogen ion in patients with uric acid calculi. Clin Sci 1965; 28: 325–345
72. Kursh ED, Resnick MI. Dissolution of uric acid calculi with system alkalinization. J Urol 1984; 132: 286–287
73. Cifuentes Delatte L, Rapado A, Abehsera A, Traba ML et al. Uric acid lithiasis and gout. In: Cifuentes Delatte L, Rapado A, Hodgkinson A, eds. Urinary Calculi. Basel: Karger, 1973: 115–118
74. Coe FL, Moran E, Kavalich AG. The contribution of dietary purine over-consumption to hyperuricosuria on calcium oxalate stone-formers. J Chron Dis 1976; 29: 793–800
75. Henneman PH, Wallach S, Dempsey EF. The metabolic defect responsible for uric acid stone-formation. J Clin Invest 1962; 41: 537–542
76. Bambach CP, Robertson WG, Peacock M, Hill GL. Effect of intestinal surgery on the risk of urinary stone formation. Gut 1981; 22: 257–263
77. Pak CYC, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986; 30: 422–428
78. Rundles WR, Wyngaarden JB, Hitchings GH, Elion GB et al. Effect of xanthine oxidase inhibitor on thiopurine metabolism, hyperuricaemia and gout. Trans Assoc Am Physicians 1963; 76: 126–140
79. Godfrey RG, Rankin TJ. Uric acid renal lithiasis: management by allopurinol. J Urol 1969; 101: 643–647
80. Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones – a rare complication of allopurinol therapy. N Engl J Med 1969; 280: 426–427
81. Band PR, Silverberg DS, Henderson JF, Ulan RA et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. N Engl J Med 1970; 283: 354–357
82. Griffith DP, Musher DM, Itin C. Urease. The primary cause of infection-induced urinary stones. Investig Urol 1976; 13: 346–350
83. Robertson WG, Peacock M, Nordin BEC. Activity products in stone-forming and non-stone-forming urine. Clin Sci 1968; 32: 579–594
84. Lerner SP, Gleeson MJ, Griffith DP. Infection stones. J Urol 1989; 141: 753–758
85. Cox CE. Urinary tract infection and renal lithiasis. Urol Clin N Am 1974; 1: 279–297
86. Chinn RH, Maskell R, Mead JE, Polak A. Renal stone and urinary infection: a study of antibiotic treatment. BMJ 1976; 2: 1411–1413
87. Griffith DP, Gibson JR, Clinton CW, Musher DM. Acetohydroxamic acid: clinical studies of a urease inhibitor in patients with staghorn renal calculi. J Urol 1978; 119: 9–15
88. Martelli A, Buli P, Cortecchia V. Urease inhibitor therapy in infected renal stones. Eur Urol 1981; 7: 291–293
89. Griffith DP, Gleeson MJ, Lee H, Longuet R et al. Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infectioninduced urinary calculi. Euro Urol 1991; 20: 243–247
90. Kinney AB, Blount M. Effect of cranberry juice on urinary pH. Nurs Res 1979; 28: 287–290
91. Pak CYC, Sakhaee K, Crowther C, Brinkley L. Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann Intern Med 1980; 93: 36–39
92. Jaeger P, Portmann L, Jacquet AF, Burckhardt P. Drinking water for stone-formers: is the calcium content relevant? Eur Urol 1984; 10: 53–54
93. Marshall RW, Cochran M, Robertson WG, Hodgkinson A et al. The relation between urine saturation and stone composition in patients with calciumcontaining renal stones. Clin Sci 1972; 43: 433–441
94. Albright F, Henneman P, Benedict PH, Forbes AP. Idiopathic hypercalciuria. Proc R Soc Med 1953; 46: 1077–1081
95. Hodgkinson A, Pyrah LN. The urinary excretion of calcium and inorganic phosphate in 344 patients with calcium stone of renal origin. Br J Surg 1958; 46: 10–18
96. Pak CYC, Kaplan RA, Bone H, Townsend J et al. A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med 1975; 292: 497–500
97. Coe FL, Favus MJ. Idiopathic hypercalciuria in calcium nephrolithiasis. Disease-a-Month 1980; 26: 1–36
98. Halabé A, Sutton RAL. Primary hyperparathyroidism and idiopathic hypercalciuria. Miner Electrolyte Metab 1987; 13: 235–241
99. Robertson WG, Peacock M. The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria? Nephron 1980; 26: 105–110
100. Rose GA. Current trends in urolithiasis research. In: Rous SN, ed. Stone Disease: Diagnosis and Management. Orlando, FL: Grune & Stratton, 1987: 383–416
101. Rudman D, Kutner MH, Redd SC, Waters WC et al. Hypocitraturia in calcium nephrolithiasis. J Clin Endocrinol Metab 1982; 1052–1057
102. Nicar MJ, Skurla C, Sakhaee K, Pak CYC. Low urinary citrate excretion in nephrolithiasis. Urology 1983; 21: 8–14
103. Hosking DH, Wilson JW, Liedtke RR, Smith LH et al. Urinary citrate excretion in normal persons and patients with idiopathic calcium urolithiasis. J Lab Clin Med 1985; 106: 682–689
104. Tiselius H-G, Almgård LE, Larsson L, Sörbo B. A biochemical basis for grouping of patients with urolithiasis. Eur Urol 1978; 4: 241–249
105. Robertson WG, Peacock M, Heyburn PJ, Marshall DH et al. Risk factors in calcium stone disease of the urinary tract. Br J Urol 1978; 50: 449–454
106. Robertson WG. A simplified procedure for assessing the biochemical risk of forming stones in patients with uric acid or calcium-containing urinary calculi. In: Borghi L, Meschi T, Briganti A, Schianci T et al, eds. Kidney Stones. Cosenza: Editoriale Bios, 1999: 403–406
107. Coe FL, Kavalich AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 1974; 291: 1344–1350
108. Grover PK, Ryall RL. Urate and calcium oxalate stones: from repute to rhetoric to reality. Miner Electrolyte Metab 1994; 20: 361–370
109. Prince CL, Scardino PL, Wolan CT. The effect of temperature, humidity and dehydration on the formation of renal calculi. J Urol 1956; 75: 209–215
110. Robertson WG, Peacock M, Marshall RW, Speed R et al. Seasonal variations in the composition of urine in relation to calcium stone-formation. Clin Sci Mol Med 1975; 49: 597–602
111. Pierce LW, Bloom B. Observations on urolithiasis among American troops in a desert area. J Urol 1945; 54: 466–470
112. Blacklock NJ. The pattern of urolithiasis in the Royal Navy. In: Hodgkinson A, Nordin BEC, eds. Proceedings of the Renal Stone Research Symposium. London: Churchill, 1969: 33–47
113. Brundig P, Berg W, Schneider HJ. Stress und Harnsteinbildungsrisiko. I. Einfluss von Stress auf lithogene Harnsubstanz. Urol Int 1981; 36: 199–207
114. Larsen JF, Phillip J. Studies on the incidence of urolithiasis. Urol Int 1962; 13: 53–54
115. Clark JY. Renal calculi in army aviators. Aviat Space Environ Med 1990; 61: 744–747
116. Robertson WG, Peacock M, Hodgkinson A. Dietary changes and the incidence of urinary calculi in the UK between 1958 and 1976. J Chron Dis 1979; 32: 469–476
117. Robertson WG, Peacock M, Baker M, Marshall DH et al. Studies on the prevalence and epidemiology of urinary stone disease in men in Leeds. Br J Urol 1983; 55: 595–598
118. Power C, Barker DJP, Blacklock NJ. Incidence of renal stones in 18 British towns. Br J Urol 1987; 59: 105–110
119. Robertson WG, Peacock M, Heyburn PJ, Hanes FA et al. Should recurrent calcium oxalate stone-formers become vegetarians? Br J Urol 1979; 51: 427–443
120. Robertson WG, Peacock M, Marshall DH. Prevalence of urinary stone disease in vegetarians. Eur Urol 1982; 8: 334–339
121. Robertson WG. Diet and calcium stones. Miner Electrolyte Metab 1987; 13: 228–234
122. Iguchi M, Umekawa IT, Ishikawa T, Katayama Y et al. Dietary intake and habits of Japanese renal stone patients. J Urol 1990; 143: 1093–1095
123. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993; 328: 833–838
124. Resnick MI, Pridgen DB, Goodman HO. Genetic predisposition to formation of calcium oxalate renal calculi. N Engl J Med 1968; 278: 1313–1318
125. Coe FL, Parks JH, Moore ES. Familial idiopathic hypercalciuria. N Engl J Med 1979; 300: 337–340
126. Aladjem M, Modan M, Lusky A, Georgi R et al. Idiopathic hypercalciuria: a familial generalized renal hyperexcretory state. Kidney Int 1983; 24: 549–554
127. Blacklock NJ. Epidemiology of renal lithiasis. In: Wickham JEA, ed. Urinary Calculous Disease. Edinburgh: Churchill Livingstone,1979: 21–39
128. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones – medical progress. N Engl J Med 1992; 327: 1142–1152
129. Fine JK, Pak CYC, Preminger GM. Effect of medical management and residual fragments on recurrent stone formation following shock wave lithotripsy. J Urol 1995; 153: 27–33
130. Pak CYC. Kidney stones. Lancet 1998; 351: 1797–1801
131. Robertson WG. Is it possible to motivate patients with recurrent stones to adhere to their treatment regimen? In: Rodgers AL, Hibbert BE, Hess B, Khan S et al, eds. Urolithiasis 2000. Cape Town: University of Cape Town, 2000: 624–627
132. Norman RW, Bath SS, Robertson WG, Peacock M. When should patients with symptomatic stone disease be evaluated metabolically? J Urol 1984; 132: 1137–1139